Loading the recordsβ¦
Loading the recordsβ¦
BILL ANALYSIS
HR6130 (ASAP Act) has been assessed with a bullish outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.
bullish
Market Sentiment
5/10
Impact Score
1
Sectors Impacted
ASAP Act mandates Medicare coverage for blood-based dementia tests β no cash-pay barrier for seniors starting 2028.
Primary beneficiaries: Labcorp ($LH) and Quest ($DGX), the two independent labs with existing FDA-cleared blood-based dementia tests.
Bill is early stage but has 82 cosponsors + Senate companion β strong bipartisan momentum for mid-2027 passage.
QuidelOrtho ($QDEL) and Revvity ($RVTY) have diagnostics exposure but lack direct FDA-cleared dementia blood tests β secondary beneficiaries at best.
Both $LH and $DGX have declined over the past 30 days (LH: -3.62% to $257.16; DGX: -2.55% to $191). This is NOT driven by dementia policy news; it reflects general market weakness in the healthcare services sector. The ASAP Act is a positive fundamental catalyst that is not yet priced into these stocks. As the bill progresses through committee and toward passage, the market should begin to price in the incremental revenue from mandatory Medicare coverage. Investors should view current price levels as attractive entry points given the de-risked regulatory pathway (FDA-cleared tests already exist) and the certainty of the January 1, 2028 effective date if passed.
| Metric | Value |
|---|---|
| Bill Number | HR6130 |
| Market Sentiment | bullish |
| Event Date | |
| Affected Sectors | Healthcare |
| Source | View on Congress.gov β |
The ASAP Act (HR6130) mandates Medicare coverage for FDA-cleared blood-based dementia screening tests starting Jan 1, 2028. Labcorp ($LH) and Quest Diagnostics ($DGX) are the two largest independent lab operators with existing FDA-cleared blood-based dementia tests, making them primary beneficiaries of this new mandatory benefit category. The bill is in early legislative stages (referred to committee) with companion bill S3267 in the Senate, but the bipartisan sponsorship and 82 cosponsors indicate strong momentum for a mid-2027 passage timeline.
Free β no credit card
HillSignal scores every bill, federal contract, and insider filing for market impact and emails you the high-conviction ones. Free, no credit card.
Weekly digest β the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan Β· No credit card Β· Unsubscribe in one click
Want the live terminal too? Create a free account β
Β© 2026 HillSignal. All rights reserved.
Not financial advice. For informational purposes only.